JP2011505796A - ワクチン - Google Patents

ワクチン Download PDF

Info

Publication number: JP2011505796A
Authority: JP; Japan
Prior art keywords: protein; specific; ade2; vaccine; seq
Prior art date: 2007-12-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2010536451A

Other languages

English (en)

Japanese (ja)

Inventor

コーエン，ジョセフ，ディー．

マルシャン，マルティーヌ

Original Assignee

グラクソスミスクラインバイオロジカルズソシエテアノニム

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-06

Filing date

2008-12-04

Publication date

2011-03-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011505796(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-12-04 Application filed by グラクソスミスクラインバイオロジカルズソシエテアノニム filed Critical グラクソスミスクラインバイオロジカルズソシエテアノニム

2011-03-03 Publication of JP2011505796A publication Critical patent/JP2011505796A/ja

Status Pending legal-status Critical Current

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 37
108090000623 proteins and genes Proteins 0.000 claims abstract description 68
102000004169 proteins and genes Human genes 0.000 claims abstract description 62
239000000203 mixture Substances 0.000 claims abstract description 61
239000013598 vector Substances 0.000 claims abstract description 44
239000002671 adjuvant Substances 0.000 claims abstract description 38
239000000427 antigen Substances 0.000 claims abstract description 36
108091007433 antigens Proteins 0.000 claims abstract description 36
102000036639 antigens Human genes 0.000 claims abstract description 36
201000004792 malaria Diseases 0.000 claims abstract description 33
239000013603 viral vector Substances 0.000 claims abstract description 30
241000223960 Plasmodium falciparum Species 0.000 claims abstract description 25
238000004519 manufacturing process Methods 0.000 claims abstract description 16
229930182490 saponin Natural products 0.000 claims abstract description 13
150000007949 saponins Chemical class 0.000 claims abstract description 13
230000002265 prevention Effects 0.000 claims abstract description 11
239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 11
239000012634 fragment Substances 0.000 claims abstract description 8
230000002950 deficient Effects 0.000 claims abstract description 6
230000010076 replication Effects 0.000 claims abstract description 6
241000990167 unclassified Simian adenoviruses Species 0.000 claims abstract 5
238000009472 formulation Methods 0.000 claims description 41
230000000638 stimulation Effects 0.000 claims description 17
238000000034 method Methods 0.000 claims description 15
239000002502 liposome Substances 0.000 claims description 8
239000000546 pharmaceutical excipient Substances 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 5
239000007764 o/w emulsion Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 4
230000037452 priming Effects 0.000 claims 1
230000001902 propagating effect Effects 0.000 claims 1
208000015181 infectious disease Diseases 0.000 abstract description 7
230000005867 T cell response Effects 0.000 description 109
238000011748 CB6F1 mouse Methods 0.000 description 67
230000004044 response Effects 0.000 description 48
235000018102 proteins Nutrition 0.000 description 45
108090000695 Cytokines Proteins 0.000 description 43
102000004127 Cytokines Human genes 0.000 description 43
241000699670 Mus sp. Species 0.000 description 30
210000004899 c-terminal region Anatomy 0.000 description 24
210000004027 cell Anatomy 0.000 description 23
230000005875 antibody response Effects 0.000 description 21
210000001744 T-lymphocyte Anatomy 0.000 description 17
230000003053 immunization Effects 0.000 description 17
238000002649 immunization Methods 0.000 description 17
108010002350 Interleukin-2 Proteins 0.000 description 16
CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 16
108090000765 processed proteins & peptides Proteins 0.000 description 16
241001135569 Human adenovirus 5 Species 0.000 description 15
101150106931 IFNG gene Proteins 0.000 description 15
108091034117 Oligonucleotide Proteins 0.000 description 13
239000002773 nucleotide Substances 0.000 description 12
125000003729 nucleotide group Chemical group 0.000 description 12
239000013612 plasmid Substances 0.000 description 12
210000003046 sporozoite Anatomy 0.000 description 11
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
239000000556 agonist Substances 0.000 description 10
239000002245 particle Substances 0.000 description 10
102000004196 processed proteins & peptides Human genes 0.000 description 10
235000017709 saponins Nutrition 0.000 description 10
125000003275 alpha amino acid group Chemical group 0.000 description 8
235000001014 amino acid Nutrition 0.000 description 8
150000001413 amino acids Chemical class 0.000 description 8
230000005847 immunogenicity Effects 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
239000013642 negative control Substances 0.000 description 7
241000701161 unidentified adenovirus Species 0.000 description 7
102100037850 Interferon gamma Human genes 0.000 description 6
108010074328 Interferon-gamma Proteins 0.000 description 6
229930182558 Sterol Natural products 0.000 description 6
102100039360 Toll-like receptor 4 Human genes 0.000 description 6
238000000684 flow cytometry Methods 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
229940035032 monophosphoryl lipid a Drugs 0.000 description 6
210000004897 n-terminal region Anatomy 0.000 description 6
210000005259 peripheral blood Anatomy 0.000 description 6
239000011886 peripheral blood Substances 0.000 description 6
150000003432 sterols Chemical class 0.000 description 6
235000003702 sterols Nutrition 0.000 description 6
241000255925 Diptera Species 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000003308 immunostimulating effect Effects 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 4
230000028993 immune response Effects 0.000 description 4
108091033319 polynucleotide Proteins 0.000 description 4
102000040430 polynucleotide Human genes 0.000 description 4
239000002157 polynucleotide Substances 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
241000282693 Cercopithecidae Species 0.000 description 3
241000598171 Human adenovirus sp. Species 0.000 description 3
108090001030 Lipoproteins Proteins 0.000 description 3
102000004895 Lipoproteins Human genes 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
101710137302 Surface antigen S Proteins 0.000 description 3
102000002689 Toll-like receptor Human genes 0.000 description 3
108020000411 Toll-like receptor Proteins 0.000 description 3
241000235013 Yarrowia Species 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
230000036039 immunity Effects 0.000 description 3
229960001438 immunostimulant agent Drugs 0.000 description 3
239000003022 immunostimulating agent Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
241001092142 Molina Species 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
241000235648 Pichia Species 0.000 description 2
241000224016 Plasmodium Species 0.000 description 2
206010057190 Respiratory tract infections Diseases 0.000 description 2
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102100024333 Toll-like receptor 2 Human genes 0.000 description 2
-1 alkyl glucosaminide phosphates Chemical class 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
FOTKYAAJKYLFFN-UHFFFAOYSA-N decane-1,10-diol Chemical compound OCCCCCCCCCCO FOTKYAAJKYLFFN-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
229940124735 malaria vaccine Drugs 0.000 description 2
210000003936 merozoite Anatomy 0.000 description 2
239000000693 micelle Substances 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
150000007523 nucleic acids Chemical group 0.000 description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
241000894007 species Species 0.000 description 2
229940044616 toll-like receptor 7 agonist Drugs 0.000 description 2
229940044655 toll-like receptor 9 agonist Drugs 0.000 description 2
230000014616 translation Effects 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
IJFVSSZAOYLHEE-UHFFFAOYSA-N 2,3-di(dodecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-UHFFFAOYSA-N 0.000 description 1
CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical group ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
101150116940 AGPS gene Proteins 0.000 description 1
208000010370 Adenoviridae Infections Diseases 0.000 description 1
206010060931 Adenovirus infection Diseases 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
101710117490 Circumsporozoite protein Proteins 0.000 description 1
241000759568 Corixa Species 0.000 description 1
102100031262 Deleted in malignant brain tumors 1 protein Human genes 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
101710145505 Fiber protein Proteins 0.000 description 1
101100024440 Globodera rostochiensis MSP-3 gene Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000844721 Homo sapiens Deleted in malignant brain tumors 1 protein Proteins 0.000 description 1
101001130441 Homo sapiens Ras-related protein Rap-2a Proteins 0.000 description 1
101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
241000235649 Kluyveromyces Species 0.000 description 1
241001138401 Kluyveromyces lactis Species 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
108010057081 Merozoite Surface Protein 1 Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical group CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
HCUVEUVIUAJXRB-UHFFFAOYSA-N OC1=C(C=C(CNC(CCCC=2SC=CC=2)=O)C=C1)OC Chemical compound OC1=C(C=C(CNC(CCCC=2SC=CC=2)=O)C=C1)OC HCUVEUVIUAJXRB-UHFFFAOYSA-N 0.000 description 1
241000320412 Ogataea angusta Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108010013639 Peptidoglycan Proteins 0.000 description 1
240000009188 Phyllostachys vivax Species 0.000 description 1
101000983333 Plasmodium falciparum (isolate NF54) 25 kDa ookinete surface antigen Proteins 0.000 description 1
241001505483 Plasmodium falciparum 3D7 Species 0.000 description 1
241000223980 Plasmodium falciparum NF54 Species 0.000 description 1
241001454523 Quillaja saponaria Species 0.000 description 1
235000009001 Quillaja saponaria Nutrition 0.000 description 1
102100022851 Rab5 GDP/GTP exchange factor Human genes 0.000 description 1
102100031420 Ras-related protein Rap-2a Human genes 0.000 description 1
101710203837 Replication-associated protein Proteins 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
241000219287 Saponaria Species 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
241000235347 Schizosaccharomyces pombe Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108700005078 Synthetic Genes Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
210000000447 Th1 cell Anatomy 0.000 description 1
108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
108010060888 Toll-like receptor 2 Proteins 0.000 description 1
102000008230 Toll-like receptor 3 Human genes 0.000 description 1
102100024324 Toll-like receptor 3 Human genes 0.000 description 1
108010060885 Toll-like receptor 3 Proteins 0.000 description 1
102100039390 Toll-like receptor 7 Human genes 0.000 description 1
102100033110 Toll-like receptor 8 Human genes 0.000 description 1
229940122089 Toll-like receptor 8 agonist Drugs 0.000 description 1
208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000007792 addition Methods 0.000 description 1
208000011589 adenoviridae infectious disease Diseases 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
101150078331 ama-1 gene Proteins 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
210000003162 effector t lymphocyte Anatomy 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
230000005802 health problem Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229960002751 imiquimod Drugs 0.000 description 1
DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000004899 motility Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229950010550 resiquimod Drugs 0.000 description 1
BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
208000037369 susceptibility to malaria Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003970 toll like receptor agonist Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Public Health (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)

JP2010536451A 2007-12-06 2008-12-04 ワクチン Pending JP2011505796A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US99280207P	2007-12-06	2007-12-06
PCT/EP2008/066762 WO2009071613A2 (en)	2007-12-06	2008-12-04	Vaccine

Publications (1)

Publication Number	Publication Date
JP2011505796A true JP2011505796A (ja)	2011-03-03

Family

ID=40591828

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2010536451A Pending JP2011505796A (ja)	2007-12-06	2008-12-04	ワクチン

Country Status (20)

Country	Link
EP (1)	EP2227550A2 (es)
JP (1)	JP2011505796A (es)
KR (1)	KR20100108544A (es)
CN (1)	CN101939438A (es)
AR (1)	AR069568A1 (es)
AU (1)	AU2008333208A1 (es)
BR (1)	BRPI0819889A2 (es)
CA (1)	CA2707245A1 (es)
CL (1)	CL2008003614A1 (es)
CO (1)	CO6300795A2 (es)
CR (1)	CR11537A (es)
DO (1)	DOP2010000164A (es)
IL (1)	IL205953A0 (es)
MA (1)	MA32003B1 (es)
MX (1)	MX2010006207A (es)
PE (1)	PE20091106A1 (es)
TW (1)	TW200938633A (es)
UY (1)	UY31510A1 (es)
WO (1)	WO2009071613A2 (es)
ZA (1)	ZA201003851B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0815872D0 (en) *	2008-09-01	2008-10-08	Pasteur Institut	Novel method and compositions
GB201016471D0 (en) *	2010-09-30	2010-11-17	Isis Innovation	Viral vector immunogenic compositions
CA2832307A1 (en)	2011-04-08	2012-10-18	Immune Design Corp.	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110687289B (zh) *	2019-10-17	2023-04-18	中国人民解放军陆军军医大学	Fgl2蛋白作为疟疾感染标志物的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004055187A1 (en) *	2002-12-17	2004-07-01	Crucell Holland B.V.	Recombinant viral-based malaria vaccines
JP2006512405A (ja) *	2002-10-23	2006-04-13	グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム	マラリアに対するワクチン接種の方法
WO2006040334A1 (en) *	2004-10-14	2006-04-20	Crucell Holland B.V.	Malaria prime/boost vaccines
WO2007003384A1 (en) *	2005-06-30	2007-01-11	Glaxosmithkline Biologicals Sa	Anti-malaria vaccine
WO2007110409A1 (en) *	2006-03-27	2007-10-04	Crucell Holland B.V.	Compositions comprising a recombinant adenovirus and an adjuvant
WO2008107370A1 (en) *	2007-03-02	2008-09-12	Glaxosmithkline Biologicals S.A.	Novel method and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040136963A1 (en) *	2001-06-22	2004-07-15	The Trustees Of The University Of Pennsylvania	Simian adenovirus vectors and methods of use
WO2005063805A1 (en) *	2003-12-23	2005-07-14	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
EP1711518B1 (en) *	2004-01-23	2009-11-18	Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.	Chimpanzee adenovirus vaccine carriers
WO2008009652A2 (en) *	2006-07-18	2008-01-24	Glaxosmithkline Biologicals S.A.	Vaccines for malaria
GB0706914D0 (en) *	2007-04-10	2007-05-16	Isis Innovation	Novel adenovirus vectors

2008
- 2008-12-04 EP EP08857977A patent/EP2227550A2/en not_active Withdrawn
- 2008-12-04 TW TW097147198A patent/TW200938633A/zh unknown
- 2008-12-04 CA CA2707245A patent/CA2707245A1/en not_active Abandoned
- 2008-12-04 CL CL2008003614A patent/CL2008003614A1/es unknown
- 2008-12-04 AR ARP080105281A patent/AR069568A1/es not_active Application Discontinuation
- 2008-12-04 MX MX2010006207A patent/MX2010006207A/es not_active Application Discontinuation
- 2008-12-04 AU AU2008333208A patent/AU2008333208A1/en not_active Abandoned
- 2008-12-04 BR BRPI0819889-6A patent/BRPI0819889A2/pt not_active IP Right Cessation
- 2008-12-04 UY UY31510A patent/UY31510A1/es unknown
- 2008-12-04 PE PE2008002018A patent/PE20091106A1/es not_active Application Discontinuation
- 2008-12-04 KR KR1020107014859A patent/KR20100108544A/ko not_active Withdrawn
- 2008-12-04 CN CN2008801267101A patent/CN101939438A/zh active Pending
- 2008-12-04 JP JP2010536451A patent/JP2011505796A/ja active Pending
- 2008-12-04 WO PCT/EP2008/066762 patent/WO2009071613A2/en not_active Ceased
2010
- 2010-05-25 IL IL205953A patent/IL205953A0/en unknown
- 2010-05-28 ZA ZA2010/03851A patent/ZA201003851B/en unknown
- 2010-06-02 DO DO2010000164A patent/DOP2010000164A/es unknown
- 2010-06-10 CO CO10070274A patent/CO6300795A2/es not_active Application Discontinuation
- 2010-06-29 CR CR11537A patent/CR11537A/es not_active Application Discontinuation
- 2010-07-05 MA MA32991A patent/MA32003B1/fr unknown

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006512405A (ja) *	2002-10-23	2006-04-13	グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム	マラリアに対するワクチン接種の方法
WO2004055187A1 (en) *	2002-12-17	2004-07-01	Crucell Holland B.V.	Recombinant viral-based malaria vaccines
WO2006040334A1 (en) *	2004-10-14	2006-04-20	Crucell Holland B.V.	Malaria prime/boost vaccines
WO2007003384A1 (en) *	2005-06-30	2007-01-11	Glaxosmithkline Biologicals Sa	Anti-malaria vaccine
WO2007110409A1 (en) *	2006-03-27	2007-10-04	Crucell Holland B.V.	Compositions comprising a recombinant adenovirus and an adjuvant
WO2008107370A1 (en) *	2007-03-02	2008-09-12	Glaxosmithkline Biologicals S.A.	Novel method and compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013046280; ＳｃｉｅｎｃｅＶｏｌ．２２５, 1984, ｐ．５９３-５９９ *

Also Published As

Publication number	Publication date
AR069568A1 (es)	2010-02-03
MA32003B1 (fr)	2011-01-03
WO2009071613A2 (en)	2009-06-11
CR11537A (es)	2010-08-18
BRPI0819889A2 (pt)	2015-06-16
MX2010006207A (es)	2010-10-04
CA2707245A1 (en)	2009-06-11
DOP2010000164A (es)	2010-07-31
IL205953A0 (en)	2010-11-30
AU2008333208A1 (en)	2009-06-11
PE20091106A1 (es)	2009-08-24
UY31510A1 (es)	2009-08-03
CL2008003614A1 (es)	2010-01-15
ZA201003851B (en)	2012-11-28
TW200938633A (en)	2009-09-16
CO6300795A2 (es)	2011-07-21
KR20100108544A (ko)	2010-10-07
WO2009071613A3 (en)	2009-08-13
EP2227550A2 (en)	2010-09-15
CN101939438A (zh)	2011-01-05

Publication	Publication Date	Title
US20100272786A1 (en)	2010-10-28	Vaccine
JP5592110B2 (ja)	2014-09-17	マラリア用ワクチン
US20100272745A1 (en)	2010-10-28	Vaccines for malaria
JP2011505796A (ja)	2011-03-03	ワクチン
US8999347B2 (en)	2015-04-07	Vaccines for malaria
CN101553249A (zh)	2009-10-07	用于疟疾的疫苗

Legal Events

Date	Code	Title	Description
2011-12-03	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111202
2013-09-18	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130917
2013-12-11	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131210
2013-12-18	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131217
2014-06-04	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140603